中科天元(01156.HK)接獲復牌指引 續停牌
中科天元(01156.HK)公布,於5月5日收到聯交所列明復牌指引,要求公司對核數師提出的審計問題進行適當的獨立調查、評估對業務經營及財務狀況之影響、公佈調查結果並採取適當補救行動;根據上市規則規定刊發所有尚未公佈的財務業績及處理任何審核修訂;證明公司遵守上市規則第13.24條規定;及通知市場所有重要資訊,以供股東及其他投資者評估公司狀況。
中科天元表示,將盡力達致復牌指引所載之條件,完全遵守上市規則以令聯交所信納,並將盡快恢復其股份買賣。
應公司要求,股份已由2021年4月1日起於聯交所暫停買賣,並將繼續暫停買賣直至另行通知為止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.